Rocket Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Rocket Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Rocket Pharmaceuticals Inc recorded a cumulative net loss of $-17 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -4.71%.

However, within the Healthcare sector 260 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4018, from total ROA ranking in the first quarter of 2026 at 4661.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	15.52 %	-39 %	-36.91 %	-6.1 %	-5.77 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-17	-209	-223	-241	-257
Return On Assets (TTM)	-4.71 %	-59.84 %	-56.41 %	-54.28 %	-57.2 %
RCKT's Total Ranking	# 4018	# 4661	# 4061	# 4147	# 4225
Total Assets (TTM) in million	482	285	330	366	417
Seq. Total Assets Change	68.98 %	-13.63 %	-9.78 %	-12.27 %	-10.77 %
Seq. Net Income Change	-	-	-	-	-

RCKT's 5 Years Annual ROA >> Back to RCKT Management Effectiveness >> Compare RCKT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 88
Sector	# 261
Overall	# 2956

Return On Assets Statistics
High	Average	Low
-4.9 %	-40.5 %	-79.82 %
(Jun 30 2026)		(Dec 31 2015)

Financial Statements
Rocket Pharmaceuticals Inc 's Assets	$ 482 million	RCKT's Balance sheet
Rocket Pharmaceuticals Inc 's Income	$ 123 million	Quarterly RCKT's Income Statement
RCKT's Income by Division		See RCKT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-36.91 %	-7.05 %	2.31 %	10.91 %	-28.51 %
Total Assets in million	330	524	564	551	497
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-223	-259	-246	-222	-169
Annual Return On Assets	-67.52 %	-49.4 %	-43.58 %	-40.28 %	-34.04 %

RCKT's 5 Years Annual ROA >> Back to RCKT Management Effectiveness >> Compare RCKT ROA to its Competitors

More Return On Assets Ratios
RCKT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RCKT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RCKT's Competitors
Subscribers only: Roa for Rocket Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for RCKT's Customers

You may also want to know
RCKT's Roi	RCKT's Inventory Turnover Ratio	RCKT's Growth Rates	RCKT's Dividend Comparisons
	RCKT's Profitability Ratios	RCKT's Asset Turnover Ratio	RCKT's Dividend Growth
RCKT's Roe	RCKT's Valuation Ratios	RCKT's Financial Strength Ratios	RCKT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:14:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.